Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention

Not Applicable

Active, not recruiting

• Conditions: Hereditary Breast and Ovarian Cancer Syndrome; Gynecologic Cancer; Breast Cancer; Colon Cancer; Endometrial Cancer; Uterus Cancer; Ovary Cancer; Lynch Syndrome; Pancreatic Cancer

• Registration Number: NCT05677048
• Lead Sponsor: M.D. Anderson Cancer Center

Brief Summary

This is a community-based study requiring participant-self-enrollment, that can help to increase the rates of genetic testing among the family members of people who have been diagnosed with a hereditary cancer syndrome. The two main factors in this study are the IGNITE-TX intervention (website and navigator) and the free genetic counseling and testing.

The IGNITE-TX Intervention is an innovative multi-modal intervention, with two components: a) interactive web "IGNITE-TX Hub" and b) genetic family navigators.

Detailed Description

Primary Objectives:

The primary objectives of this study are to assess the study feasibility by estimating:

1. The enrollment of probands and (ARRs) at-risk relatives over a 6-month period

2. The response rate to baseline and follow-up surveys by probands

3. The response rate to baseline and follow-up surveys by (ARRs) at-risk relatives

Secondary Objectives:

The secondary objectives of this study are to:

1. Measure (ARR) at-risk relatives completion of (CGT) cascade genetic testing among different study arms.

2. Measure the proportion of enrolled (ARRs) at-risk relatives who make an informed decision about (CGT) cascade genetic testing.

3. Measure the (ARR) at-risk relatives readiness for (CGT) cascade genetic testing

4. Measure proband and (ARR) at-risk relatives change in genetics knowledge

5. Measure proband readiness to communicate results of genetic testing with (ARR) at-risk relatives Secondary objectives in this feasibility study will be primary objectives in a larger study. This feasibility study is not powered to assess these objectives. Including them in this feasibility study will allow for assessment of our measurement tools (surveys from primary objectives) and offer insight into how the intervention may impact cascade genetic testing when implemented on a larger scale

Exploratory Objectives:

The exploratory objectives in this study are to estimate:

1. The average website traffic of the IGNITE-TX "Hub" and module completion

2. The average utilization of family genetic navigators by participants

3. Estimate the intra-familial correlation (IFC) for (ARR) at-risk relatives completion of (CGT) cascade genetic testing

4. Assess satisfaction with IGNITE-TX website modules and genetic navigator The exploratory objectives will allow for further evaluation of the IGNITE-TX website modules and navigator and understand how families with multiple (ARR)at-risk relatives respond to the intervention.

Study Timeline

• Study First Submitted: 2022-12-14
• Study First Submitted QC: 2023-01-05
• Study First Posted: 2023-01-10
• Study Start: 2023-04-14
• Status Verified: 2025-09
• Last Update Submitted: 2025-09-04
• Last Update Posted: 2025-09-08
• Primary Completion: 2025-10-31
• Study Completion: 2027-10-31

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 205

Inclusion Criteria

1. 18 years of age or older
2. Speaks and/or reads English or Spanish
3. Has known deleterious/pathogenic mutation or suspected deleterious/pathogenic variant in BRCA1 or BRCA2 (HBOC) or MLH1, MSH2, MSH6, PMS2, or EPCAM (LS)
4. Has access to the internet or phone and can send and receive email and/or text messages at a US telephone number
5. Has at least one at-risk relative who meets inclusion criteria for first-degree relative

Exclusion Criteria

1. Has no at-risk relatives meeting inclusion criteria
2. Has negative germline genetic testing or only variant of uncertain significance
3. Unwilling or unable to provide consent 4.2. AT-RISK RELATIVES (ARR)

Inclusion Criteria:

1. 18 years of age or older
2. Speaks and reads English or Spanish
3. Resides in the United States
4. Can provide proof of deleterious/suspected deleterious HBOC or LS variant present in a first degree relative (biological mother or father, biological child, or full sibling)
5. Has access to internet or phone and can send and receive email and/or text messages at a US telephone number

Exclusion Criteria:

1. Unwilling or unable to provide consent
2. Reports no known HBOC or LS variant within the family
3. Has already been tested for the variant identified in the proband
4. Already listed as an ARR for another proband

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: FACTORIAL

Primary Outcome Measures

Name	Time	Method
Measure response rate to baseline and follow-up surveys by probands and at-risk relatives	Up to 6 months
Measure enrollment of probands and at-risk relatives over a 6-month period	Up to 6 months

Trial Locations

Locations (1)

MD Anderson Cancer Center; 🇺🇸 Houston, Texas, United States